MedTech Terms
    The authoritative reference
    All terms
    ManufacturingManufacturing & SupplyCCI

    Container Closure Integrity

    Demonstration that a sterile package maintains microbial barrier and contents integrity over the labeled shelf life.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    CCI testing methods (dye ingress, helium leak, vacuum decay, microbial challenge) confirm that the sterile barrier system protects sterility. ISO 11607 references CCI methods; package validation must address transport hazards in addition to long-term stability. ISO 11607-1 covers the design and validation of sterile barrier systems, and ISO 11607-2 covers the forming, sealing and assembly processes. Deterministic methods such as vacuum decay and helium leak testing are preferred over probabilistic ones like dye ingress because they are more sensitive and repeatable. Distribution testing often follows ASTM D4169 or ISTA.
    What the regulation says
    Container Closure Integrity (CCI) is a critical aspect of sterile medical device packaging, as recognized by standards such as ISO 11607, "Packaging for terminally sterilized medical devices." Regulatory bodies like the FDA emphasize that package validation must demonstrate a package's ability to maintain sterility over its shelf life and through simulated distribution, aligning with requirements in 21 CFR Part 820, Quality System Regulation. The EU MDR, in Annex I, General Safety and Performance Requirements, also necessitates that devices be designed and produced in a way that does not compromise their sterility at the point of use.

    What this means in practice

    CCI failures are a leading cause of recalls and field corrections in sterile-packaged devices.

    Examples

    • A manufacturer performs a dye ingress test on a sterile blister package after accelerated aging to assess its CCI over the product's shelf life.
    • During package validation, a helium leak test is conducted on a sterile syringe system to detect very small leaks that could compromise sterility.
    • A medical device company uses a microbial challenge test to demonstrate that its packaging system can prevent the ingress of bacteria under worst-case conditions.
    Common pitfalls
    • •Failing to integrate CCI testing into a comprehensive package validation plan can lead to regulatory non-compliance.
    • •Ignoring the impact of manufacturing process variations on CCI can result in compromised sterile barriers.
    • •Selecting CCI test methods that are not sensitive or appropriate for the specific device and package design can provide a false sense of security.
    • •Not considering the effects of transportation and handling stresses on CCI can lead to sterility breaches in the field.
    • •Delaying CCI testing until the final stages of design and manufacturing can lead to costly rework and project delays.

    Frequently asked questions

    The primary purpose of CCI testing is to confirm that the sterile barrier system effectively protects the sterility of a medical device throughout its shelf life and distribution, preventing ingress of contaminants.

    Related terms

    Grouped by theme
    Cited by

    Where this term appears across MedTech Terms.

    Sources

    3 sources

    Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

    Tier 1Binding law and standards· 2Tier 2Regulator guidance and consensus· 1
    Link health: 3 verified· last checked 2026-06-20
    ISO·2IMDRF/GHTF·1
    1. 1
      ISO 11607-1
      Tier 1 Verified
      ISOiso.org
    2. 2
      ISO 13485 Standard Page
      Tier 1 Verified
      ISOiso.org
    3. 3
      GHTF/IMDRF Process Validation Guidance
      Tier 2 Verified
      IMDRF/GHTFimdrf.org

    Inline markers like [1] jump to the matching reference above.